Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Multiple Sclerosis

  Free Subscription


18.02.2019

1 BMC Neurol
2 Brain
1 J Immunol
1 J Neurol
3 Mult Scler
1 Neurology
1 PLoS One
4 Rev Neurol (Paris)


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    BMC Neurol

  1. HEMOND CC, Glanz BI, Bakshi R, Chitnis T, et al
    The neutrophil-to-lymphocyte and monocyte-to-lymphocyte ratios are independently associated with neurological disability and brain atrophy in multiple sclerosis.
    BMC Neurol. 2019;19:23.
    PubMed     Text format     Abstract available


    Brain

  2. MEXHITAJ I, Nyirenda MH, Li R, O'Mahony J, et al
    Abnormal effector and regulatory T cell subsets in paediatric-onset multiple sclerosis.
    Brain. 2019 Feb 12. pii: 5316384. doi: 10.1093.
    PubMed     Text format     Abstract available

  3. KADOWAKI A, Saga R, Lin Y, Sato W, et al
    Gut microbiota-dependent CCR9+CD4+ T cells are altered in secondary progressive multiple sclerosis.
    Brain. 2019 Feb 15. pii: 5321131. doi: 10.1093.
    PubMed     Text format     Abstract available


    J Immunol

  4. LI R, Rezk A, Ghadiri M, Luessi F, et al
    Correction: Dimethyl Fumarate Treatment Mediates an Anti-Inflammatory Shift in B Cell Subsets of Patients with Multiple Sclerosis.
    J Immunol. 2019 Feb 15. pii: jimmunol.1900114. doi: 10.4049/jimmunol.1900114.
    PubMed     Text format    


    J Neurol

  5. JAKIMOVSKI D, Weinstock-Guttman B, Gandhi S, Guan Y, et al
    Dietary and lifestyle factors in multiple sclerosis progression: results from a 5-year longitudinal MRI study.
    J Neurol. 2019 Feb 13. pii: 10.1007/s00415-019-09208.
    PubMed     Text format     Abstract available


    Mult Scler

  6. JAKIMOVSKI D, Ramanathan M, Weinstock-Guttman B, Bergsland N, et al
    Higher EBV response is associated with more severe gray matter and lesion pathology in relapsing multiple sclerosis patients: A case-controlled magnetization transfer ratio study.
    Mult Scler. 2019 Feb 13:1352458519828667. doi: 10.1177/1352458519828667.
    PubMed     Text format     Abstract available

  7. CICERO CE, Patti F, Lo Fermo S, Giuliano L, et al
    Lack of association between Toxocara canis and multiple sclerosis: A population-based case-control study.
    Mult Scler. 2019 Feb 11:1352458518825394. doi: 10.1177/1352458518825394.
    PubMed     Text format    

  8. SOTIRCHOS ES, Gonzalez-Caldito N, Dewey BE, Fitzgerald KC, et al
    Effect of disease-modifying therapies on subcortical gray matter atrophy in multiple sclerosis.
    Mult Scler. 2019 Feb 11:1352458519826364. doi: 10.1177/1352458519826364.
    PubMed     Text format     Abstract available


    Neurology

  9. BERGER T, Stuve O
    Neurofilament light chain: An important step toward a disease biomarker in multiple sclerosis.
    Neurology. 2019 Feb 8. pii: WNL.0000000000007022.
    PubMed     Text format    


    PLoS One

  10. POPESCU DC, Huang H, Singhal NK, Shriver L, et al
    Vitamin K enhances the production of brain sulfatides during remyelination.
    PLoS One. 2018;13:e0203057.
    PubMed     Text format     Abstract available


    Rev Neurol (Paris)

  11. GOUT O
    Should we treat patients with radiologically isolated syndrome (RIS)? No.
    Rev Neurol (Paris). 2018 Nov 16. pii: S0035-3787(18)30706.
    PubMed     Text format    

  12. LEBRUN C, Bertagna M, Bresch S, Cohen M, et al
    Digestive side-effects with teriflunomide: Thoughts on lactose.
    Rev Neurol (Paris). 2018;174:722-725.
    PubMed     Text format     Abstract available

  13. THOUVENOT E
    Should we treat patients with radiologically isolated syndrome (RIS)? Yes.
    Rev Neurol (Paris). 2018 Jul 2. pii: S0035-3787(18)30705.
    PubMed     Text format    

  14. LEBRUN C
    Should we treat patients with radiologically isolated syndrome (RIS)? Comments.
    Rev Neurol (Paris). 2018 May 17. pii: S0035-3787(18)30612.
    PubMed     Text format    


Thank you for your interest in scientific medicine.


AMEDEO Multiple Sclerosis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: